Mitochondrial-targeted plastoquinone therapy prevents early onset muscle weakness that occurs before atrophy during ovarian cancer

Mitochondrial-targeted plastoquinone therapy prevents early onset muscle weakness that occurs before atrophy during ovarian cancer

Objective: Muscle loss with cancer causes weakness, worsens quality of life, and predicts reduced overall survival rates. Recently, muscle weakness was identified during early-stage cancer before atrophy develops. This discovery indicates that mechanisms independent of muscle loss must contribute to...

Full description

Saved in:
Bibliographic Details
Main Authors: Luca J. Delfinis, Shahrzad Khajehzadehshoushtar, Luke D. Flewwelling, Nathaniel J. Andrews, Madison C. Garibotti, Shivam Gandhi, Aditya N. Brahmbhatt, Brooke A. Morris, Bianca Garlisi, Sylvia Lauks, Caroline Aitken, Leslie Ogilvie, Stavroula Tsitkanou, Jeremy A. Simpson, Nicholas P. Greene, Arthur J. Cheng, Jim Petrik, Christopher G.R. Perry
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Molecular Metabolism
Subjects:
Ovarian cancer cachexia
Mitochondria
Skeletal muscle
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877825001188
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2212877825001188

Similar Items